News

The RECEIVE study develops tools to standardize returning chest CT results in the Lung Health Cohort, improving engagement and ethical practices.

With a completed 12-week analysis, Outlook Therapeutics plans to resubmit the Biologics License Application for ONS-5010 in the first quarter of 2025.

This cohort study’s findings shed light on associated factors with acne relapse and retrial among individuals with acne who were treated with isotretinoin.

In the absence of effective treatments, the prevalence of MASLD could reach 41.4% by 2050 and lead to large increases in HCC cases and liver transplants.

This systematic review and meta-analysis highlighted several key findings on use of probiotics as a treatment of pediatric patients with allergies to food.

A new study shows that employee stress improves when using a mindfulness meditation app for under or above 5 minutes (the more effective option).

Dubinsky describes the evolution from anti-TNF therapies to IL-23 antagonists and the significance of mirikizumab’s approval for Crohn’s disease.

Semaglutide 7.2 mg achieved statistically significant and superior weight loss at 72 weeks versus placebo, hitting the Phase 3b trial's primary endpoint.

Medicare has selected 15 additional drugs to negotiate prices directly with participating drug companies, including semaglutide (Ozempic).

Despite the surge in telemental health use in patients with schizophrenia, fewer people in racial or ethnic minority groups had a telemental health visit compared to White people.

The study leverages large US-based claims datasets and pathologist input to estimate the annual incidence and total prevalence of IgAN in the US.

Shadi Kourosh, MD, MPH, joins The Medical Sisterhood to discuss advocacy, mentorship, and the empowerment of women in medicine.

In this episode, hosts explore ADA's evolving guidelines championing broader access to CGM and AID systems for personalized diabetes care.

Boehringer Ingelheim’s phase 3 trial of iclepertin for cognitive impairment in schizophrenia failed to meet primary and secondary endpoints, showing no significant effects.

These data highlight current applications of AI and machine learning in aesthetic medicine, looking specifically at studies graded as Level I or II.

Current asthma diagnosis requires specialized breathing tests that can be challenging for young children.

In a validated microsimulation model, annual CRC screening with FIT was the most cost-effective strategy among patients with low adherence.

UCB announced that a new dosing option for bimekizumab-bkzx is now available through prescription for conditions such as psoriasis, hidradenitis suppurativa, and psoriatic arthritis.

Axatilimab in 9 mg and 22 mg vial sizes are expected to launch in early February for the treatment of chronic graft-versus-host disease.

A study shows the causal link between apoA-I and chronic obstructive pulmonary disease, showing lipid metabolism's role in the pathogenesis of COPD.

Based on NHANES data, the age-adjusted prevalence of lean SLD was found to be 12.8%, including a 9.8% prevalence of lean MASLD.

A new study showed ADHD incidence trends fluctuated between 2016-2023, with adult diagnoses rising post-COVID-19 and adolescent rates remaining stable after an initial decline.

With a Phase 3 trial expected in 2025, linsitinib is the first oral small-molecule therapy to demonstrate statistical significance in thyroid eye disease.

The approval is based on data from the phase 3 VIVID-1 study and marks mirikizumab’s second approval in IBD, the first being ulcerative colitis in 2023.

This study pointed to the abilities of patients with acne to adapt to stress and adversity as helpful in making skin-related quality of life improvements.

Anti-CGRP monoclonal antibodies for migraine prevention were not linked to increased cardiovascular risk, per a Medicare study, addressing earlier safety concerns.

A cohort study with 14 years of follow-up found monogenic and polygenic mechanisms influencing LDL-C and incident T2D risk inversely associated.

The analysis of UnitedHealth Group claims data found the per-patient cost of cirrhosis care exceeded that of HF and COPD by 21.7% and 55.0%, respectively.